Improving outcomes in AL amyloidosis
Transcript: Highlights from ISA 2022
Professor Giovanni Palladini
All transcripts are created from interview footage and directly reflect the content of the interview at the time. The content is that of the speaker and is not adjusted by Medthority.
Well, I think overall this was a very interesting and very important meeting. So what I really appreciated was the involvement of different... Of doctors, of physicians, from different specialties. It was very nice to have that together. Haematologists, cardiologists, nephrologists, and many, many other specialists. I think the ISA meeting is the, almost, the only opportunity to gather together and discussing the disease from different perspectives. But this is really important in amyloidosis, which is a systemic disease, and I would say in all amyloidosis that were discussed there. So multidisciplinary involvement is probably the most striking positive result that we had from the meeting. Also, the meeting was the opportunity to present new strategies. I already mentioned the trials on ATTR amyloidosis, the APOLLO-B trial of patisiran in cardiac ATTR, but also ongoing trials, such as the trials with anti-amyloid antibodies in amyloidosis for now.
And also the place to talk about perspectives in the treatment, CAR T, venetoclax, new Bcl-2 inhibitors, and new diagnostic procedures, imaging, for instance, and new technologies for typing. And of course, early diagnosis, which was emphasised. The ISA meeting is also the meeting of the Society, of the International Society of Amyloidosis. So this was the place to discuss what the Society did in the past two years and what the Society is planning to do in the next couple of years. And I think our society is becoming really more active and more important in the international scenario. And given we are now moving, as I said, to the era of evidence-based medicine, the fact that this society is working issuing on guidelines is very important. Referral centres are still necessary in rare diseases such as systemic amyloidosis. But one of our role is also to create networks that can bring high-quality care to patients near their places of residence. And guidelines are one of the instruments that we can use to do so.
Developed independently by EPG Health, which received an educational grant from Alexion, awarded to EPG Health to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.
Updates in your area
of interest
of interest
Articles your peers
are looking at
are looking at
Bookmarks
saved
saved
Days to your
next event
next event